Anti-protamine-heparin antibodies: Incidence, clinical relevance, and pathogenesis

Blood

Volumn 121, Issue 15, 2013, Pages 2821-2827

  Bakchoul, Tamam ^a   Zöllner, Heike ^a   Amiral, Jean ^b   Panzer, Simon ^c   Selleng, Sixten ^a   Kohlmann, Thomas ^d   Brandt, Sven ^d   Delcea, Mihaela ^d   Warkentin, Theodore E ^e,f   Sachs, Ulrich J ^g   Greinacher, Andreas ^a  

^a UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^b SYSMEX CORPORATION   (Japan)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITY OF GREIFSWALD   (Germany)

^e MCMASTER UNIVERSITY   (Canada)

^f MCMASTER UNIVERSITY   (Canada)

^g JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ARGATROBAN; HEPARIN; HEPARIN ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; PROTAMINE; PROTAMINE ANTIBODY; UNCLASSIFIED DRUG; HEPARIN ANTAGONIST; IMMUNOGLOBULIN G; THROMBOCYTE FACTOR 4;

ADULT; ANIMAL EXPERIMENT; ARTICLE; CARDIOPULMONARY BYPASS; CIRCULAR DICHROISM; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOCYTE LIFESPAN; THROMBOCYTOPENIA; THROMBOEMBOLISM; AGED; ANIMAL; BLOOD; CHEMICALLY INDUCED DISORDER; ENZYME IMMUNOASSAY; IMMUNOLOGY; INCIDENCE; METHODOLOGY; MOUSE MUTANT; NONOBESE DIABETIC MOUSE; THROMBOCYTE TRANSFUSION; TIME; XENOGRAFT;

AGED; ANIMALS; ANTIBODIES; CARDIOPULMONARY BYPASS; FEMALE; HEPARIN; HEPARIN ANTAGONISTS; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOGLOBULIN G; INCIDENCE; MALE; MICE; MICE, INBRED NOD; MICE, SCID; MIDDLE AGED; PLATELET COUNT; PLATELET FACTOR 4; PLATELET TRANSFUSION; PROTAMINES; THROMBOCYTOPENIA; TIME FACTORS; TRANSPLANTATION, HETEROLOGOUS;

MLCS; MLOWN;

EID: 84878656687     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-10-460691     Document Type: Article

References (37)

1. Kimmel SE, Sekeres MA, Berlin JA, et al. Adverse events after protamine administration in patients undergoing cardiopulmonary bypass: risks and predictors of under-reporting. J Clin Epidemiol. 1998;51(1):1-10. (Pubitemid 28026509)
2. Bull BS, Korpman RA, Huse WM, et al. Heparin therapy during extracorporeal circulation. I. Problems inherent in existing heparin protocols. J Thorac Cardiovasc Surg. 1975;69(5):674-684.
3. Deykin D. Regulation of heparin therapy. N Engl J Med. 1972;287(7):355-356.
4. Deykin D. Current concepts: the use of heparin. N Engl J Med. 1969;280(17):937-938.
5. Arepally GM, Ortel TL. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med. 2006;355(8):809-817.
6. Ellerhorst JA, Comstock JP, Nell LJ. Protamine antibody production in diabetic subjects treated with NPH insulin. Am J Med Sci. 1990;299(5):298-301. (Pubitemid 20166482)
7. Nell LJ, Thomas JW. Frequency and specificity of protamine antibodies in diabetic and control subjects. Diabetes. 1988;37(2):172-176. (Pubitemid 18066600)
8. Bakchoul T, Giptner A, Krautwurst A, et al. In vivo animal model of drug-induced thrombocytopenia: the clinical relevance of anti-protamine sulfate antibodies. J Thromb Haemost. 2011;9(S2,):
9. Amiral J, Peyrafitte M, Vissac A. Association of protamine sulfate antibodies with 'Pseudo-HIT' in heparin treated patients. Haemostaseologie. 2009; PP4.4-9:A65 (Abstract).
10. Chudasama SL, Espinasse B, Hwang F, et al. Heparin modifies the immunogenicity of positively charged proteins. Blood. 2010;116(26):6046-6053.
11. Greinacher A. Heparin-induced thrombocytopenia. J Thromb Haemost. 2009;7(Suppl 1):9-12.
12. Selleng S, Malowsky B, Itterman T, et al. Incidence and clinical relevance of anti-platelet factor 4/heparin antibodies before cardiac surgery. Am Heart J. 2010;160(2):362-369.
13. Greinacher A, Michels I, Kiefel V, et al. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thromb Haemost. 1991;66(6):734-736.
14. Juhl D, Eichler P, Lubenow N, et al. Incidence and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia. Eur J Haematol. 2006;76(5):420-426.
15. Prechel M, Hilby A, Walenga J. Cross reactivity of heparin-induced PF4 antibodies with heparin-bound IL-8. In: Proceedings from the American Society of Hematology; December 6-9, 2008; San Francisco, CA. Abstract 3429. [Abstract]
16. Boylan B, Chen H, Rathore V, et al. Anti-GPVI-associated ITP: an acquired platelet disorder caused by autoantibody-mediated clearance of the GPVI/FcRgamma-chain complex from the human platelet surface. Blood. 2004;104(5):1350-1355. (Pubitemid 39166510)
17. Bakchoul T, Boylan B, Sachs UJ, et al. Blockade of maternal anti-HPA-1a-mediated platelet clearance by an HPA-1a epitope-specific F(ab′) in an in vivo mouse model of alloimmune thrombocytopenia. Transfusion. 2009;49(2):265-270.
18. Greinacher A, Ittermann T, Bagemühl J, et al. Heparin-induced thrombocytopenia: towards standardization of platelet factor 4/heparin antigen tests. J Thromb Haemost. 2010;8(9):2025-2031.
19. Warkentin TE. How I diagnose and manage HIT. Hematology Am Soc Hematol Educ Program. 2011;2011:143-149.
20. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia and cardiac surgery. Ann Thorac Surg. 2003;76(2):638-648. (Pubitemid 36960635)
21. Lee GM, Welsby IJ, Phillips Bute B, et al. High incidence of antibodies to protamine and protamine/heparin complexes in patients undergoing cardiopulmonary bypass [published online ahead of print Feb 19, 2013]. Blood. doi:10.1182/blood-2012-11-469130.
22. Pouplard C, Leroux D, Rollin J, et al. Incidence of antibodies to protamine/heparin complexes in cardiac surgery patients and impact on platelet activation in vitro and clinical outcome. In: Proceedings of the American Society of Hematology; December 10-13, 2011; San Diego, CA. Abstract 2217. [Abstract]
23. Butterworth J, Lin YA, Prielipp R, et al. The pharmacokinetics and cardiovascular effects of a single intravenous dose of protamine in normal volunteers. Anesth Analg. 2002;94(3):514-522. (Pubitemid 34177542)
24. Butterworth J, Lin YA, Prielipp RC, et al. Rapid disappearance of protamine in adults undergoing cardiac operation with cardiopulmonary bypass. Ann Thorac Surg. 2002;74(5):1589-1595. (Pubitemid 35222646)
25. Warkentin TE, Kelton JG. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med. 2001;135(7):502-506. (Pubitemid 32923567)
26. Rauova L, Hirsch JD, Greene TK, et al. Monocyte-bound PF4 in the pathogenesis of heparininduced thrombocytopenia. Blood. 2010;116(23):5021-5031.
27. Subramaniam P, Skillington P, Tatoulis J. Heparin-rebound in the early postoperative phase following cardiopulmonary bypass. Aust N Z J Surg. 1995;65(5):331-333.
28. Nurden P, Poujol C, Durrieu-Jais C, et al. Labeling of the internal pool of GP IIb-IIIa in platelets by c7E3 Fab fragments (abciximab): flow and endocytic mechanisms contribute to the transport. Blood. 1999;93(5):1622-1633. (Pubitemid 29102490)
29. Greinacher A, Fuerll B, Zinke H, et al. Megakaryocyte impairment by eptifibatide-induced antibodies causes prolonged thrombocytopenia. Blood. 2009;114(6):1250-1253.
30. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med. 2001;344(17):1286-1292. (Pubitemid 32372963)
31. Collins C, O'Donnell A. Does an allergy to fish pre-empt an adverse protamine reaction? A case report and a literature review. Perfusion. 2008;23(6):369-372.
32. Knape JT, Schuller JL, de Haan P, et al. An anaphylactic reaction to protamine in a patient allergic to fish. Anesthesiology. 1981;55(3):324-325. (Pubitemid 11049300)
33. Nell LJ, Hulbert C, Arem R, et al. Factors affecting the insulin autoantibody ELISA. Autoimmunity. 1989;2(4):299-309. (Pubitemid 19101898)
34. Levy JH, Schwieger IM, Zaidan JR, et al. Evaluation of patients at risk for protamine reactions. J Thorac Cardiovasc Surg. 1989;98(2):200-204. (Pubitemid 19198523)
35. Greinacher A. Opposites attract. Blood. 2010;115(3):440-441.
36. Krauel K, Pötschke C, Weber C, et al. Platelet factor 4 binds to bacteria, [corrected] inducing antibodies cross-reacting with the major antigen in heparin-induced thrombocytopenia. Blood. 2011;117(4):1370-1378.
37. Krauel K, Weber C, Brandt S, et al. Platelet factor 4 binding to lipid A of Gram-negative bacteria exposes PF4/heparin-like epitopes. Blood. 2012;120(16):3345-3352.